10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Bladder Cancer
8 articles
Pembrolizumab Boosts Disease-Free Survival in High-Risk Urothelial Carcinoma Post-Surgery
Adjuvant pembrolizumab improves disease-free survival in high-risk muscle-invasive urothelial carcinoma patients
CheckMate 274: Nivolumab Boosts Survival in High-Risk Urothelial Cancer
Phase III trial shows adjuvant nivolumab improves disease-free survival in high-risk urothelial carcinoma.
Durvalumab Boosts Survival in Muscle-Invasive Bladder Cancer: NIAGARA Trial Results
Immunotherapy drug durvalumab improves outcomes for muscle-invasive bladder cancer when added to chemotherapy
Biomarker Breakthrough: TMB and PD-L1 Predict Immunotherapy Success in Advanced Bladder Cancer
Study reveals TMB and PD-L1 as potential biomarkers for immunotherapy response in urothelial carcinoma
Breakthrough Combo Therapy Revolutionizes Advanced Bladder Cancer Treatment
New drug combination shows superior survival benefit for advanced bladder cancer in global trial.
New Bladder Cancer Treatment Slashes Recurrence Rates: Promising Results from Egyptian Trial
Study shows neoadjuvant EMDA of mitomycin C before TURBT may reduce bladder cancer recurrence vs BCG alone.
Immunotherapy Combo Boosts Survival in Advanced Bladder Cancer
Adding nivolumab to chemotherapy improves outcomes for patients with metastatic urothelial carcinoma
Erdafitinib Outperforms Chemo for Advanced Bladder Cancer with FGFR Mutations
Erdafitinib improves survival vs. chemo in metastatic urothelial cancer with FGFR alterations